CN Mobile Logo

Search form


Breast Cancer

Pertuzumab Combo Improved Invasive DFS in HER2-Positive Breast Cancer

The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease–free survival in patients with HER2-positive early breast cancer.

Gunter von Minckwitz, MD, PhD, presenting results of the trial; photo © ASCO/Scott Morgan 2017

Breast Cancer

To universally recommend breast irradiation for all women after excision of DCIS lesions ignores information now available to us that can spare the majority of women with DCIS the downsides of RT, but be applied in the treatment of DCIS patients at greater risk for invasive disease.

At this time RT following BCS remains the standard of care for most patients. Current tools, including prognostic scores and tumor genetics, have failed to identify a cohort for whom RT confers no benefit with respect to invasive recurrences.

Low levels of cytotoxic stromal tumor-infiltrating lymphocytes are predictive of benefit derived from antibody- vs small molecule–based drug approaches to HER2-positive metastatic breast cancer.

Breast cancer subtypes generally did not respond differently to radiotherapy following breast-conserving surgery, according to long-term follow-up of a randomized trial.

The FDA Oncologic Drugs Advisory Committee has unanimously voted to recommend approval of the trastuzumab biosimilar MYL-1401O for the treatment of HER2-positive breast cancer.

The FDA has approved neratinib (Nerlynx) for use as extended adjuvant treatment in adult patients with early-stage HER2-positive breast cancer.

The use of bisphosphonates was not associated with a decrease in the incidence of breast cancer in postmenopausal women, contrary to hypothesis.


Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.